Application of oridonin in preparation of cardiac remodeling resistant medicines

A technology of oridonin and cardiomyocytes, applied in the field of medicine and cell biology, to achieve the effects of low cardiotoxicity, delaying cardiomyocyte hypertrophy, and less drug dosage

Active Publication Date: 2017-09-15
WUHAN UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cardiomyocytes are terminally differentiated cells, and their cell cycle, metabolic patterns, and signal transduction pathways are very different from tumor cells. At present, there is no research on Rubescensine A for myocardial remodeling drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oridonin in preparation of cardiac remodeling resistant medicines
  • Application of oridonin in preparation of cardiac remodeling resistant medicines
  • Application of oridonin in preparation of cardiac remodeling resistant medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1 Rubescensine A detects the toxicity of isolated cardiomyocytes

[0031] (1) Primary cardiomyocyte culture

[0032] The SD suckling mice within 3 days after birth were disinfected with 75% alcohol, and the heart was removed by opening the chest on the ultra-clean workbench, washed with DMEM / F12 medium and cut into 1-2mm 3 Add 8ml of diluted trypsin digestion solution, heat in a water bath on a magnetic stirrer at a speed of 150rpm, digest for 15 minutes, rest for a few seconds and discard the supernatant containing impurities, then repeat the digestion step and absorb the cardiomyocyte digestion solution, add In the pre-cooled DMEM / F12 medium containing 20% ​​FBS, the digestion was repeated 4-5 times, and the collected cardiomyocyte suspension was collected.

[0033] Centrifuge the collected cardiomyocyte suspension at 1500rpm for 8 minutes, discard the supernatant and add an appropriate amount of medium to resuspend the cells, then filter through a 40μm filt...

Embodiment 2

[0046] Example 2 Effect of Rubescensine A on Hypertrophy of Isolated Cardiomyocytes

[0047] Myocardial remodeling is manifested as an increase in the volume of cardiomyocytes at the cellular level, and the increase in cell volume is mainly due to the abnormal transcription of hypertrophy-related genes caused by various factors. Isolated neonatal rat cardiomyocytes can represent the pathophysiological changes in somatic cells to a certain extent; Ang II is the main neurohumoral stimulating factor when the heart is subjected to long-term excessive pressure load and the renin-angiotensin system is activated. Stimulating isolated cardiomyocytes with Ang II can better simulate the process of myocardial remodeling in vivo, and it can be used to observe the protective effect of oridonin on myocardial cell remodeling under pressure load. The specific simulation and verification process of this embodiment is as follows:

[0048] (1) Primary cardiomyocyte culture

[0049] As in Examp...

Embodiment 3

[0059] Example 3 Effect of In Vivo Application of Oridonin on Myocardial Hypertrophy Caused by Pressure Overload

[0060] (1) Establishment of pressure overload myocardial remodeling model in mice and administration of oridonin

[0061] A pressure load-induced myocardial remodeling model was established by thoracic aortic coarctation. Male C57 mice aged 8-10 weeks and weighing 23.5-27.5g were included in the experiment, and were randomly divided into 4 groups, with 10-12 mice in each group, as follows:

[0062] ①Sham operation without drug treatment group (Sham Veh),

[0063] ②Sham-operated oridonin-administered group (Sham Ori);

[0064] ③ AB operation without medication group (AB Veh),

[0065] ④ AB surgery oridonin A administration group (AB Ori).

[0066]Among them, in the AB operation group (including the AB operation without drug addition group and the AB operation oridonin A administration group), the mice were anesthetized, skin prepared, non-invasive tracheal intu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of oridonin in preparation of cardiac remodeling resistant medicines as well as a cardiac remodeling resistant medicine taking oridonin as a unique active ingredient or a main active ingredient. The invention provides novel medicinal use of the oridonin for preparing the cardiac remodeling resistant medicine. The oridonin can achieve the effects of alleviating cardiac remodeling, inhibiting or delaying cardiomyocyte hypertrophy and cardiac interstitial fibrosis caused by a pressure load, protecting the heart and preventing deterioration of the cardiac function. The oridonin has the advantages of obvious cardiac remodeling resistant effect, low cardiotoxicity and the like.

Description

technical field [0001] The invention relates to the technical fields of medicine and cell biology, in particular to the use of oridonin in the preparation of anti-myocardial remodeling drugs. Background technique [0002] Cardiovascular disease is a major problem in global public health. According to statistics, in 2014, the death rate of cardiovascular disease in China still ranked first among various diseases, higher than that of tumors and other diseases; with the improvement of diagnosis and treatment, coupled with the aging population and the national With the widespread exposure of cardiovascular risk factors, the number of people living with cardiovascular disease in my country has increased, and the burden of cardiovascular disease has continued to increase rapidly. However, existing drugs or interventional treatments for cardiovascular diseases have their own disadvantages, and it is urgent to seek new methods for the prevention and treatment of cardiovascular disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P9/00
CPCA61K31/352
Inventor 唐其柱徐蔓万春霞黄思慧
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap